.

Professor Michael J. Tisdale

Professor of Cancer Biochemistry

Member of the Pharmacy and Biology Teaching Programmes

School of Life & Health Sciences
Aston University
Aston Triangle
Birmingham
B4 7ET
UK

email: M.J.Tisdale@aston.ac.uk
telephone: +44 (0) 121 204 4021
fax: +44 (0) 121 204 3743

Research Theme

Chronic and Communicable Conditions

Research Centre

Aston Research Centre for Healthy Ageing (ARCHA)

tisdalmj-1.jpg

I joined the Cancer Research Campaign Experimental Chemotherapy Group in the Department of Pharmacy at Aston University as Senior Research Fellow in October 1980.  Prior to that I spent 8 years as Lecturer in the Department of Biochemistry at St Thomas’s Hospital Medical School, University of London, one year as Scientific Officer at Rothamstead Experimental Station, Harpenden and one year as MRC Fellow at the Institute of Cancer Research.

  • BSc (lst Class Honours) (Chemistry), Hull, 1967
  • PhD (Chemistry), London, 1970
  • DSc (Cancer Biochemistry), London, 1983

• 1989–date: Professor of Cancer Biochemistry, Aston University
• 1992-95: Head of Department, Pharmaceutical and Biological Sciences, Aston  University
• 1984-89: Reader, Department of Pharmaceutical Sciences, Aston University 
• 1981-84: Senior Research Fellow, CRC Experimental Chemotherapy Group, Aston  University
• 1972-81: Lecturer Department of Biochemistry, St Thomas’s Medical School
• 1971-72: Scientific Officer, Rothamstead Experimental Station
• 1970-71: MRC Fellow, Institute of Cancer Research

Mainly related to cancer causation, biology treatment and associated conditions e.g. cachexia.

Modules: PH3 CM1, PH1 CM1, BY3 CM1, BY1 CM1, BY2 BD1, PH3 MC1

Cancer cachexia, mechanism and treatment.  Treatment of obesity and type 2 diabetes.

Specifically:

• Signal transduction pathways involved in muscle catabolism by proteolysis-inducing factor (PIF)
• Cloning and sequencing of cellular receptor for PIF
• Cloning and expression of PIF
• Investigation of antibodies to the PIF receptor as anticachectic agents
• Action of eicosapentaenoic acid (EPA) in preventing muscle catabolism by PIF
• Role of EPA in attenuating muscle catabolism in catabolic states other than cancer cachexia
• Clinical evaluation of EPA in the treatment of cancer cachexia

Awarding Body

Title of Project

Amount (£)

Dates

Halsa Pharmaceuticals

Evaluation of zinc-alpha 2-glycoprotein for the treatment of obesity

220,000

2008-2010

Bioneris

Anticachectic activity of a novel agent

135,000

2006-2009

Ross Products Division

Effect of ingredients in an animal model of cachexia

490,536

2002-2008

British Technology Group

Studies on the PIF receptor

74,986

2005

Novartis Medical Nutrition

Investigation into the mechanism for depression of protein synthesis in cancer

152,404

2004-2007

Ark Therapeutics

To determine whether angiotensin II has a direct effect on muscle protein degradation

142, 528

2003-2005

Bayer Healthcare

The potential therapeutic use of zinc-alpha2-glcyoprotein for obesity and type II diabetes

196,868

2002-2004

Lustgarten Foundation

Cloning and expression of a muscle receptor for a cancer-cachectic factor

50,655

2003

Novartis Consumer Health

Studies on cancer cachexia

131,964

2003-2004


Recent Publications